SCHEMBL3939477

SCHEMBL3939477

Nc1nccc(-c2cc3ccccc3s2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 2/20 0.60
CCNT1 O60563 1/20 0.58
CCNA2 P20248 1/20 0.58
CDK2 P24941 1/20 0.58
CDK9 P50750 1/20 0.58
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
ROCK1 Q13464 2/20 0.51
GSK3B P49841 1/20 0.51
CYP19A1 P11511 1/20 0.51
IKBKB O14920 5/20 0.50
CHUK O15111 3/20 0.50
IKBKG Q9Y6K9 3/20 0.50
APP P05067 1/20 0.50
AURKA O14965 1/20 0.50
HSP90AA1 P07900 1/20 0.50
PRKACA P17612 1/20 0.50
ADORA2A P29274 1/20 0.50
MAPKAPK2 P49137 2/20 0.48
GRM4 Q14833 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13977726 0.86 CDC7 (0.63) CDC7CCNT1CCNA2CDK2CDK9
SCHEMBL3963946 0.81 CYP19A1 (0.51) CDC7CCNT1CCNA2CDK2CDK9
SCHEMBL9237890 0.78 APP (0.59) CDC7CYP19A1IKBKBCHUKIKBKG
SCHEMBL4194172 0.77 CDC7 (1.00) CDC7CCNT1CCNA2CDK2CDK9
SCHEMBL403651 0.76 CYP19A1 (0.60) KDM4EALDH1A1CYP19A1IKBKBCHUK
SCHEMBL29415478 0.76 CYP19A1 (0.60) KDM4EALDH1A1CYP19A1IKBKBCHUK
SCHEMBL16200263 0.75 CYP19A1 (0.52) CDC7CCNT1CCNA2CDK2CDK9
SCHEMBL18942000 0.75 CCNT1 (1.00) CCNT1CCNA2CDK2CDK9
SCHEMBL2986306 0.75 IKBKB (0.48) CDC7CYP19A1IKBKBCHUKIKBKG
SCHEMBL2517455 0.75 CYP19A1 (0.59) KDM4EALDH1A1CYP19A1IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101309918-B [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases LILLY CO ELI 2010-12-29 CN disclosed
US-7547691-B2 [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases ELI LILLY AND COMPANY (US) 2009-06-16 US disclosed
EP-2044061-A2 BENZOTHIOPHENE INHIBITORS OF RHO KINASE Kahraman, Mehmet (US) 2009-04-08 EP disclosed
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases ELI LILLY AND COMPANY 2008-12-11 US disclosed
CN-101309918-A [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases LILLY CO ELI (US) 2008-11-19 CN disclosed
WO-2008011560-A2 BENZOTHIOPHENE INHIBITORS OF RHO KINASE KAHRAMAN MEHMET (US) 2008-01-24 WO disclosed
WO-2008011560-A2 BENZOTHIOPHENE INHIBITORS OF RHO KINASE KAHRAMAN MEHMET (US) 2008-01-24 WO disclosed
US-20080021026-A1 BENZOTHIOPHENE INHIBITORS OF RHO KINASE Kahraman, Mehmet (US) 2008-01-24 US disclosed
US-20080021026-A1 BENZOTHIOPHENE INHIBITORS OF RHO KINASE Kahraman, Mehmet (US) 2008-01-24 US disclosed
US-20080021026-A1 BENZOTHIOPHENE INHIBITORS OF RHO KINASE Kahraman, Mehmet (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306082-A1 [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases NFKBIA, IKBKB, IKBKG CDC7 785/4885CCNT1 1256/4885CCNA2 859/4885
US-20080021026-A1 BENZOTHIOPHENE INHIBITORS OF RHO KINASE RHOT2, ROCK2, ROCK1 CDC7 420/4885CCNT1 747/4885CCNA2 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.